KRAS and cancer: A recent study by Wong et al. also reveals that glutamine metabolism in mutant KRAS CRC cells contributes to the activation of Wnt signaling, cancer stemness, and drug resistance by reducing DNA methylation through SLC25A22, a mitochondrial glutamine transporter (Wong et al., 2020).